文献速递产科麻醉术前评估与围术期医学

去甲肾上腺素与去氧肾上腺素在剖宫产脊麻中的新生儿结局:随机双盲实用性非劣效研究

Norepinephrine or phenylephrine during spinal anaesthesia for Caesarean delivery: a randomised double-blind pragmatic non-inferiority study of neonatal outcome.
PubMed 文献 · Br J Anaesth · 2020-07-15

该随机双盲非劣效试验纳入668例脊麻或腰硬联合麻醉下剖宫产产妇,比较去甲肾上腺素与去氧肾上腺素治疗低血压对新生儿结局的影响。主要终点脐动脉血pH在去甲肾上腺素组不劣于去氧肾上腺素组(均值7.289 vs 7.287,组间差值0.002,95%CI -0.005至0.009,P=0.017)。亚组分析支持择期病例的非劣效性,非择期病例结论不确定。

要点

  • 去甲肾上腺素与去氧肾上腺素均可用于剖宫产脊麻低血压,脐动脉血pH非劣效。
  • 非劣效界值为0.01个pH单位,组间差值0.002(95%CI -0.005至0.009)。
  • 非择期病例的亚组分析结果不确定,需谨慎解读。

核心结论

  • 去甲肾上腺素在新生儿结局(以脐动脉血pH评估)方面不劣于去氧肾上腺素。
  • 结果为去甲肾上腺素在产科麻醉中的胎儿安全性提供了高质量证据。

研究设计与样本

  • 随机、双盲、双臂平行、非劣效临床试验,纳入668例择期和非择期剖宫产产妇。
  • 麻醉方式为脊麻或腰硬联合麻醉,随机分组使用去甲肾上腺素6 μg ml-1或去氧肾上腺素100 μg ml-1维持动脉血压。

主要发现

  • 664例完成研究(择期531例,非择期133例);去甲肾上腺素组332例提供351份脐动脉血样本,去氧肾上腺素组332例提供343份样本。
  • 脐动脉血pH去甲肾上腺素组均值7.289(95%CI 7.284-7.294),去氧肾上腺素组均值7.287(95%CI 7.281-7.292)。
  • 组间平均差值0.002(95%CI -0.005至0.009;P=0.017)。
  • 亚组分析证实去甲肾上腺素在择期病例中非劣效,非择期病例结论不确定。

关键数值与推荐

  • 主要终点为非劣效界值0.01个单位的脐动脉血pH。
  • 去甲肾上腺素组脐动脉血pH均值7.289(95%CI 7.284-7.294),去氧肾上腺素组均值7.287(95%CI 7.281-7.292)。
  • 组间平均差值0.002(95%CI -0.005至0.009),P=0.017,满足非劣效。

临床怎么用

  • 剖宫产脊麻期间可使用去甲肾上腺素治疗低血压,新生儿酸中毒风险不高于去氧肾上腺素。
  • 对非择期剖宫产使用去甲肾上腺素时,应结合个体情况评估,因亚组证据不确定。

局限性

  • 非择期病例亚组分析结论不确定。
  • 脐动脉血样本数(去甲肾上腺素组351份,去氧肾上腺素组343份)与完成研究的受试者数(各332例)不完全对应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Norepinephrine is an effective vasopressor during spinal anaesthesia for Caesarean delivery. However, before it can be fully recommended, possible adverse effects on neonatal outcome should be excluded. We aimed to test the hypothesis that umbilical arterial cord pH is at least as good (non-inferior) when norepinephrine is used compared with phenylephrine for treatment of hypotension. METHODS: We enrolled 668 subjects having elective and non-elective Caesarean delivery under spinal or combined spinal-epidural anaesthesia in this randomised, double-blind, two-arm parallel, non-inferiority clinical trial. Arterial blood pressure was maintained using norepinephrine 6 μg ml-1 or phenylephrine 100 μg ml-1 according to the practice of the anaesthetist, either prophylactically or therapeutically, as an infusion or bolus. The primary outcome was umbilical arterial pH with a chosen non-inferiority margin of 0.01 units. RESULTS: Of 664 subjects (531 elective and 133 non-elective) who completed the study, umbilical arterial cord blood was analysed for 351 samples from 332 subjects in the norepinephrine group and 343 samples from 332 subjects in the phenylephrine group. Umbilical arterial pH was non-inferior in the norepinephrine group (mean, 7.289; 95% confidence interval [CI], 7.284-7.294) compared with the phenylephrine group (mean, 7.287; 95% CI, 7.281-7.292) (mean difference between groups, 0.002; 95% CI, -0.005 to 0.009; P=0.017). Subgroup analysis confirmed the non-inferiority of norepinephrine for elective cases but was inconclusive for non-elective cases. CONCLUSIONS: Norepinephrine was non-inferior to phenylephrine for neonatal outcome assessed by umbilical arterial pH. These results provide high-quality evidence supporting the fetal safety of norepinephrine in obstetric anaesthesia. CLINICAL TRIAL REGISTRATION: ChiCTR-IPR-15006235.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Ngan Kee WD, Lee SWY, Ng FF, et al. Norepinephrine or phenylephrine during spinal anaesthesia for Caesarean delivery: a randomised double-blind pragmatic non-inferiority study of neonatal outcome. Br J Anaesth. 2020. PMID: 32682556. doi:10.1016/j.bja.2020.05.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。